The meeting announced below concerns Progestin Contraception and HIV Risk: Clinical and Laboratory Follow-up of a Cohort of HIV-Infected and Uninfected Women, Special Interest Project (SIP)14-023, Panel E, initial review.Start Printed Page 28522
In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:
Time and Date: 9:00 a.m.-1:00 p.m., June 4, 2014 (Closed)
Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to “Progestin Contraception and HIV risk: Clinical and Laboratory Follow-up of a Cohort of HIV-Infected and Uninfected Women, SIP14-023, Panel E, initial review.”
Contact Person for More Information: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-80, Atlanta, Georgia 30341, Telephone: (770) 488-3585, EEO6@cdc.gov.
The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 2014-11361 Filed 5-15-14; 8:45 am]
BILLING CODE 4163-18-P